Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1995-2-3
pubmed:abstractText
Fura-2-loaded human platelets were used to study Ca2+ release from intracellular compartments, as well as Ca2+ influx from the extracellular space. We investigated the response towards the endoperoxide/thromboxane-receptor agonist. U46619, and the inhibitor of the endoplasmic-reticulum Ca(2+)-ATPase, thapsigargin. U46619 dose-dependently depleted intracellular Ca2+ stores, followed by active sequestration of released Ca2+. Ca2+ influx induced by U46619 largely relies on receptor occupancy. Removing the thromboxane analogue from its receptor by using the endoperoxide/thromboxane-receptor antagonist BM 13177 largely blunted U46619-mediated Ca2+ influx. The Ca(2+)-ATPase inhibitor thapsigargin evoked a gradual rise in intracellular Ca2+, which was potentiated by a preceding activation of platelets with the receptor agonist U46619. This agonist-sensitizing effect also depends on receptor occupancy. Removing U46619 from its receptor by addition of the endoperoxide/thromboxane-receptor antagonist BM13177 suppressed the sensitizing effect completely. Furthermore, interrupting downstream receptor signalling events by raising intracellular levels of cyclic nucleotides (cyclic AMP, cyclic GMP) again suppressed the U46619-sensitizing effect on thapsigargin-induced Ca2+ release. This study indicates that the process of Ca2+ release followed by resequestration in response to a platelet agonist by its own is not sufficient to produce the sensitizing effect. Rather, a continuously occupied receptor triggering sustained downstream signalling events seems to be required for sensitization. The presence of a receptor agonist may induce an increased cycling of Ca2+ between the agonist-responsive and the thapsigargin-dischargeable compartment, leading to faster and more intense accumulation of Ca2+ in the cytosolic compartment after inhibition of the Ca(2+) ATPase. Suggestively, receptor occupancy increases the Ca(2+)-releasing potency of thapsigargin by coupling the thapsigargin-sensitive Ca(2+)-storing compartments with an agonist-responsive compartment that exhibits a high leakage rate in stimulated platelets.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1310310, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1318023, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1321718, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1325932, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1334809, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1382054, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1532033, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1647969, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1658997, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1832668, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1833401, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-1965707, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-2158766, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-2166693, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-2166695, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-2167542, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-2306207, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-2408921, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-2536184, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-2730577, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-2950855, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-2951274, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-2961610, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-3838314, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-6095092, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-6232463, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-6405111, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-6438636, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-8120005, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-8235587, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-8343120, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-8343123, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-8355806, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-8363562, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-8402906, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-8407897, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-8416943, http://linkedlifedata.com/resource/pubmed/commentcorrection/7818507-8497490
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/15-Hydroxy-11 alpha,9..., http://linkedlifedata.com/resource/pubmed/chemical/Calcium, http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP, http://linkedlifedata.com/resource/pubmed/chemical/Cyclic GMP, http://linkedlifedata.com/resource/pubmed/chemical/Epoprostenol, http://linkedlifedata.com/resource/pubmed/chemical/Nitroprusside, http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin Endoperoxides..., http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Thromboxane, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides, http://linkedlifedata.com/resource/pubmed/chemical/Terpenes, http://linkedlifedata.com/resource/pubmed/chemical/Thapsigargin, http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane A2, http://linkedlifedata.com/resource/pubmed/chemical/sulotroban
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0264-6021
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
304 ( Pt 3)
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
993-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1994
More...